EMA director still 'open-minded' on data disclosure policy
This article was originally published in SRA
As the European Medicines Agency's management board prepares to examine the agency's controversial draft policy on clinical trial data disclosure at its meeting tomorrow, the EMA's executive director Guido Rasi has said he is willing to explore more "user-friendly" approaches to allay researchers' concerns over limitations on access to trial data1.
You may also be interested in...
The head of the European Medicines Agency is nearing the end of his tenure. We consider Guido Rasi’s achievements over the past 10 years as well as the controversies that have arisen under his leadership – and report that sailing is likely to figure in his plans for life after the agency.
It hasn’t even happened yet, but Brexit has already had a huge impact on the EU regulatory network and on the life science sector operating in the EU, particularly in the UK. We look back at some of the key events over the past ten years that have woven the UK ever more closely into the EU’s tight-knit regulatory network, and why the UK’s future links with that network will remain uncertain after the country leaves the EU on 31 January.
Roche plans to appeal against a penalty imposed by the Romanian competition authorities for implementing strategies that were said to delay the entry of competing biosimilar and generic products.